Role of Repeated Oral Doses of Activated Charcoal in Clinical Toxicology

This is a preview of subscription content, access via your institution.

References

  1. Belz GB, Bader H. Effect of oral charcoal on plasma levels of intravenous methyl proscillaridin. Klinische Wochenschrift 52: 1134–1135, 1974

    PubMed  Article  CAS  Google Scholar 

  2. Berg MJ, Berlinger WG, Goldberg MJ, Spector R, Johnson GF. Acceleration of the body clearance of phenobarbital by oral activated charcoal. New England Journal of Medicine 307: 642–644, 1982

    PubMed  Article  CAS  Google Scholar 

  3. Berlinger WG, Spector R, Goldberg MJ, Johnson GF, Quee CK, et al. Enhancement of theophylline clearance by oral activated charcoal. Clinical Pharmacology and Therapeutics 33: 351–354, 1983

    PubMed  Article  CAS  Google Scholar 

  4. Caldwell JH, Caldwell P, Murphy JW, Beachler CW. Intestinal secretion of digoxin in the rat. Naunyn Schmiedeberg’s Archives of Pharmacology 312: 271–275, 1980

    PubMed  Article  CAS  Google Scholar 

  5. Chung DC, Murphy JE, Taylor TW. In vivo comparison of the adsorption capacity of ‘superactive charcoal’ and fructose with activated charcoal and fructose. Journal of Toxicology, Clinical Toxicology 19(2): 219–224, 1982

    Article  CAS  Google Scholar 

  6. Cooney DO. Activated charcoal. Antidotal and other medical uses, Marcel Dekker, New York, 1980

    Google Scholar 

  7. Cooney D. A superactive charcoal for antidotal use in poisonings. Journal of Clinical Toxicology 11(4): 387–390, 1977

    Article  CAS  Google Scholar 

  8. Cooney DO, Kane RP. Superactive charcoal adsorbs drugs as fast as standard antidotal charcoal. Journal of Clinical Toxicology 16(1): 123–125, 1980

    Article  CAS  Google Scholar 

  9. Duggan DE, Kwan KC. Enterohepatic recirculation of drugs as a determinant of therapeutic ratio. Drug Metabolism Reviews 9: 21–41, 1979

    PubMed  Article  CAS  Google Scholar 

  10. Du Souich P, Caille G, La Rochelle P. Enhancement of nadolol elimination by activated charcoal and antibiotics. Clinical Pharmacology and Therapeutics 33: 585–590, 1983

    PubMed  Article  Google Scholar 

  11. Friedman EA, Feinstein EI, Beyer MM, Galonsky RS, Hirsch SR. Charcoal-induced lipid reduction in uremia. Kidney International 13 (Suppl. 8): S170–S176, 1978

    Google Scholar 

  12. Gadgil SD, Damle SR, Advani SH, Vaidya AG. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treatment Reports 66: 1169–1171, 1982

    PubMed  CAS  Google Scholar 

  13. Gal P, Miller A, McCur JD. Oral activated charcoal to enhance theophylline elimination in an acute overdose. Journal of the American Medical Association 251: 3130–3131, 1984

    PubMed  Article  CAS  Google Scholar 

  14. Garattini S. Hepatic toxicity with TCDD. Presented at National Academy of Sciences Workshop on Plans of Clinical and Epidemological Follow Up after Areawide Chemical Contamination, Washington, DC, March, 1980

  15. Goldberg MJ, Berlinger WG. Treatment of phenobarabital overdose with activated charcoal. Journal of the American Medical Association 247: 2400–2401, 1982

    PubMed  Article  CAS  Google Scholar 

  16. Goldberg MJ, Berlinger WG, Park GD. Activated charcoal in phenobarbital overdose. Journal of the American Medical Association 253: 1120–1121, 1985

    PubMed  Article  CAS  Google Scholar 

  17. Goldberg MJ, Park GD, Spector R, Fischer LJ, Feldman RD. Lack of effect of oral activated charcoal on imipramine clearance. Clinical Pharmacology and Therapeutics 38: 350–353, 1985

    PubMed  Article  CAS  Google Scholar 

  18. Guzelian PS. New approaches for treatment of humans exposed to a slowly excreted environmental chemical (chlordecone). A. Gastroenterologie 22: 16–20, 1984

    CAS  Google Scholar 

  19. Hayden JW, Comstock EG. Use of activated charcoal in acute poisoning. Clinical Toxicology 8: 515–533, 1975

    PubMed  Article  CAS  Google Scholar 

  20. Javaid KA, El-Mabrouk BH. In vitro absorption of phenobarbital onto activated charcoal. Journal of Pharmaceutical Sciences 72: 82–85, 1983

    PubMed  Article  CAS  Google Scholar 

  21. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on sotalol pharmacokinetics. International Journal of Pharmacology, Therapy and Toxicology 22(8): 441–446, 1984

    Google Scholar 

  22. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. International Journal of Pharmacology, Therapy and Toxicology 23(4): 219–225, 1985

    Google Scholar 

  23. Klaassen CD. Biliary excretion of xenobiotics. CRC Critical Reviews in Toxicology 4: 1–30, 1975

    PubMed  CAS  Google Scholar 

  24. Kolibash AJ, Kramer WG, Reuing RH, Caldwell JH. Marked decline in serum digoxin concentration during an episode of severe diarrhea. American Heart Journal 94: 805–807, 1977

    Article  Google Scholar 

  25. Lake KD, Brown DC, Peterson CD. Digoxin toxicity: enhanced systemic elimination during oral activated charcoal therapy. Pharmacotherapy 4: 161–163, 1984

    PubMed  CAS  Google Scholar 

  26. Lalonde RS, Deshpande R, Hamilton PP, McLean WM, Greenway DC. Acceleration of digoxin clearance by activated charcoal. Clinical Pharmacology and Therapeutics 37: 367–371, 1985

    PubMed  Article  CAS  Google Scholar 

  27. Lenz K, Morz R, Kleinberger G, Pointner H, Druml W, et al. Effect of gut lavage on phenobarbital elimination in rats. Journal of Toxicology — Clinical Toxicology 20: 147–157, 1983

    PubMed  Article  CAS  Google Scholar 

  28. Levy G. Gastrointestinal clearance of drugs with activated charcoal. New England Journal of Medicine 387: 676–678, 1982

    Article  Google Scholar 

  29. Mahutte CK, True RJ, Michiels TN, Berman JN, Light RW. Increased serum theophylline clearance with orally administered activated charcoal. American Review of Respiratory Disease 128: 820–822, 1983

    PubMed  CAS  Google Scholar 

  30. Neuvonen PJ. Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clinical Pharmacokinetics 7: 465–489, 1982

    PubMed  Article  CAS  Google Scholar 

  31. Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. European Journal of Clinical Pharmacology 17: 51–57, 1980

    PubMed  Article  CAS  Google Scholar 

  32. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate and ammonium chloride on chlorpropamide kinetics. Clinical Pharmacology and Therapeutics 33: 386–393, 1983

    PubMed  Article  CAS  Google Scholar 

  33. Neuvonen PJ, Elonen E, Mattila MJ. Oral activated charcoal and dapsone elimination. Clinical Pharmacology and Therapeutics 27: 823–827, 1980

    PubMed  Article  CAS  Google Scholar 

  34. Olkkola KT, Neuvonen PJ. Do gastric contents modify antidotal efficacy of oral activated charcoal? British Journal of Clinical Pharmacology 18: 663–669, 1984

    PubMed  Article  CAS  Google Scholar 

  35. Park GD, Radomski L, Goldberg MJ, Spector R, Johnson GF, et al. Effects of size and frequency of oral doses of charcoal on theophylline clearance. Clinical Pharmacology and Therapeutics 34: 663–666, 1983

    PubMed  Article  CAS  Google Scholar 

  36. Park GD, Spector R, Goldberg MJ, Johnson GF, Feldman R, et al. Effect of the surface area of activated charcoal on theophylline clearance. Journal of Clinical Pharmacology 24(7): 289–292, 1984

    PubMed  CAS  Google Scholar 

  37. Pollack MM, Dunbar BS, Holbrook PR, Fields AI. Aspiration of activated charcoal and gastric contents. Annals of Emergency Medicine 10: 528–529, 1981

    PubMed  Article  CAS  Google Scholar 

  38. Pond SM. Diuresis dialysis and haemoperfusion: indications and benefits. Emergency Medicine Clinics of North America 2: 29–45, 1984

    PubMed  CAS  Google Scholar 

  39. Pond S, Jacobs M, Marks J, Garner J, Goldschlager N, et al. Treatment of digitoxin overdose with oral activated charcoal. Lancet 2: 1177–1178, 1981

    PubMed  Article  CAS  Google Scholar 

  40. Pond SM, Olson KR, Osterloh JD, Tong TG. Randomised study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. Journal of the American Medical Association 251: 3104–3108, 1984.

    PubMed  Article  CAS  Google Scholar 

  41. Pond SM, Osterloh JD, Olson KR, Tong TG. Activated charcoal and phenobarbital overdose. Journal of the American Medical Association 253: 1121, 1985

    Article  Google Scholar 

  42. Radomski L, Park GD, Goldberg MJ, Spector R, Johnson GF, et al. Model for theophylline overdose treatment with oral activated charcoal. Clinical Pharmacology and Therapeutics 35: 402–408, 1984

    PubMed  Article  CAS  Google Scholar 

  43. Reissel P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state tween clinical condition and blood barbiturate levels. American Journal of Clinical Pathology 24: 1133–1138, 1954

    Google Scholar 

  44. Trudnowski R, Gessner T. Mechanism for gastric accumulation of meperidine and effect of antacid. Canadian Anaesthetists’ Society Journal 27: 496–499, 1980

    PubMed  Article  CAS  Google Scholar 

  45. True RJ, Berman JN, Mahutte CK. Treatment of theophylline toxicity with oral activated charcoal. Critical Care Medicine 12: 113–114, 1984

    PubMed  Article  CAS  Google Scholar 

  46. Winchester JF, Gelfand MC, Knepshield JH, Shreiner GE. Dialysis and hemoperfusion of poisons and drugs — update. Transactions of the American Society of Artificial and Internal Organs 23: 762–842, 1977 blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Medica Scandinavica Suppl. 668: 88–90, 1982

    Article  CAS  Google Scholar 

  47. Rosenberg J, Benowitz L, Pond SM. Pharmacokinetics of drug overdose. Clinical Pharmacokinetics 6: 161–192, 1981

    PubMed  Article  CAS  Google Scholar 

  48. Rozman K, Rozman T, Greim H. Stimulation of nonbiliary, intestinal excretion of hexachlorobenzene in rhesus monkeys by mineral oil. Toxicology and Applied Pharmacology 70: 255–261, 1983

    PubMed  Article  CAS  Google Scholar 

  49. Sunshine I, Hackett ER. Barbiturate studies. II. Correlation be

  50. Yasuhara M, Kurosaki Y, Kimura T, Sezaki H. Drug elimination function of rat small intestine: metabolism and intraluminal excretion. Biochemical Pharmacology 33: 3132–3136, 1984

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr Susan M. Pond.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pond, S.M. Role of Repeated Oral Doses of Activated Charcoal in Clinical Toxicology. Medical Toxicology 1, 3–11 (1986). https://doi.org/10.1007/BF03259824

Download citation

Keywords

  • Charcoal
  • Activate Charcoal
  • Phenobarbitone
  • Digitoxin
  • Clinical Toxicology